Therefore, inhibiting the production of IL‐21 from the source can restore the suppressive function of CTLA‐4+ Tregs and GATA‐3+ Tregs, which may be beneficial to the treatment of SLE patients. Here, CTLA4 is linked to systemic lupus erythematosus.